Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer (Q44485092)

3 December 2017

title

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer (English)

1 reference

3 December 2017

Hidefumi Sasaki

1

1 reference

3 December 2017

Katsuhiko Endo

2

1 reference

3 December 2017

Katsuhiro Okuda

3

1 reference

3 December 2017

Osamu Kawano

4

1 reference

3 December 2017

Naoto Kitahara

5

1 reference

3 December 2017

Hisaichi Tanaka

6

1 reference

3 December 2017

Akihide Matsumura

7

1 reference

3 December 2017

Keiji Iuchi

8

1 reference

3 December 2017

Minoru Takada

9

1 reference

3 December 2017

Masaaki Kawahara

10

1 reference

3 December 2017

Tomoya Kawaguchi

11

1 reference

3 December 2017

Haruhiro Yukiue

12

1 reference

3 December 2017

Tomoki Yokoyama

13

1 reference

3 December 2017

Motoki Yano

14

1 reference

3 December 2017

Yoshitaka Fujii

15

1 reference

3 December 2017

language of work or name

1 reference

12 October 2007

1 reference

Journal of Cancer Research and Clinical Oncology

3 December 2017

published in

1 reference

3 December 2017

volume

134

1 reference

3 December 2017

issue

5

1 reference

3 December 2017

page(s)

569-577

1 reference

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

3 December 2017

cites work

1 reference

12 December 2020

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

12 December 2020

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer

1 reference

12 December 2020

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

12 December 2020

The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler

1 reference

12 December 2020

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

1 reference

12 December 2020

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer

1 reference

12 December 2020

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

12 December 2020

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

12 December 2020

Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay

1 reference

12 December 2020

EGFR and cancer prognosis

1 reference

12 December 2020

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

EGFR and erbB2 mutation status in Japanese lung cancer patients

1 reference

12 December 2020

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

12 December 2020

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

1 reference

12 December 2020

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

12 December 2020

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

12 December 2020

High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.

1 reference

12 December 2020

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation

1 reference

12 December 2020

10.1007/S00432-007-0320-Z

Identifiers

DOI

1 reference

3 December 2017

1 reference